Abstract. The motor neurons of patients with sporadic amyotrophic lateral sclerosis (ALS) express abundant Q/R site-unedited GluR2 mRNA, whereas those of patients with other motor neuron diseases including familial ALS associated with mutated SOD1 (ALS1) and those of normal subjects express only Q/R site-edited GluR2 mRNA. Because adenosine deaminase acting on RNA type 2 (ADAR2) specifically catalyzes GluR2 Q/R site-editing, it is likely that ADAR2 activity is not sufficient to edit this site completely in motor neurons of patients with sporadic ALS. Because these molecular abnormalities occur in disease-and motor neuron-specific fashion and induce fatal epilepsy in mice, we have hypothesized that GluR2 Q/R site-underediting due to ADAR2 underactivity is a cause of neuronal death in sporadic ALS. We found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position using RNA interference knockdown. Our review will include a discussion of new ADAR2 substrates that may be useful for research on sporadic ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive paralysis with muscle wasting due to selective loss of upper and lower motor neurons. More than 90% of cases of ALS are sporadic, while the remaining cases of ALS have more than one other affected family member (familial ALS). Gene mutations causative of familial ALS, including those of the superoxide dismutase 1 (SOD1) gene, have not been detected in the majority of sporadic cases of ALS (1) , indicating that the pathogenesis of sporadic ALS differs from that of familial ALS. Several hypotheses concerning the pathogenesis of sporadic ALS have been suggested, including those related to excitotoxicity (2), toxicity (3), autoimmunity (4), infection (5), and oxidative stress (6) . Among these, considerable evidence supports the excitotoxic hypothesis (7 -9) .
The mechanism of initiation of motor neuronal death appears to involve excessive influx of Ca 2+ through α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors (10) . The determinants of this Ca 2+ influx include the Ca 2+ permeability of AMPA receptors, which is due to the presence of the GluR2 subunit and related to the reduction of GluR2 Q/R site-editing, and the density of receptors on the cell surface, which is regulated by many factors including regulatory proteins, direct We have demonstrated that RNA editing of GluR2, a subunit of the AMPA receptor, at the Q/R site is decreased in motor neurons of a small number of sporadic ALS cases in disease-specific and neuronal class-selective fashion (12, 13) . Functional AMPA receptors are tetrameric assemblies of GluR1, GluR2, GluR3, and GluR4, in various combinations produced in nonstochastic fashion. In mammals, all GluR2 mRNAs in neurons are completely edited and the majority of AMPA receptors have GluR2 in their composition, making AMPA receptors Ca 2+ -impermeable. In the motor neurons in patients with ALS, due to underediting of GluR2 mRNA at the Q/R site, the proportion of Ca 2+ -permeable AMPA receptors may be increased, resulting in neuronal death (14) . RNA editing at the GluR2 Q/R site is specifically catalyzed by ADAR2 (15) . Reduction of this enzyme activity is probably the cause of the underediting observed in ALS motor neurons.
RNA editing and ADARs
RNA editing is a posttranscriptional modification of mRNA that alters the amino acids specified by the gene. The resulting change in amino acid residues alters the biological function of translated molecules; this is most clearly demonstrated in alterations of channel properties including those of the Ca 2+ permeability of GluRs, a subunit of AMPA, and kainate receptors (16, 17) . In human and rodent brains, the efficiency of editing at each editing site of GluRs is developmentally and regionally regulated (18 -24) , and abnormal RNA editing may result in animal or human diseases affecting the central nervous system. However, no consistent findings have been reported regarding alteration of these editing sites in the case of temporal lobe epilepsy (25) , depression (26) , and schizophrenia (27) . In contrast, abnormal editing has been demonstrated to be associated with certain neurological diseases including amyotrophic lateral sclerosis (28, 29) .
These alterations are catalyzed by the adenosine deaminases, which recognize a specific target sequence of nucleotides and convert an adenosine (A) to an inosine (I), which the ribosome translates as a guanosine (G). This A-to-I RNA editing controls a variety of biologically important mRNAs and is specifically catalyzed by either adenosine deaminase acting on RNA type 1 (ADAR1) or type 2 (ADAR2) in mammals including humans. A lot of novel A-to-I editing sites have been identified in vitro in mRNAs abundantly expressed in mammalian organs by means of computational genomic techniques (30) , although the enzyme catalyzing editing at these sites has yet to be determined.
ADAR2 predominantly catalyzes RNA editing at the Q/R site of GluR2 both in vivo and in vitro (15, 31, 32) , whereas both ADAR1 and ADAR2 catalyze the Q/R sites of GluR5 and GluR6, which are subunits of kainate receptors (15, 32) . ADAR3, a third member of the ADAR family, is exclusively expressed in the central nervous system but is catalytically inactive on both extended dsRNA and known pre-mRNA editing substrates (33, 34) .
New substrates of ADAR2
Using immunoprecipitation and the RNA interference (RNAi) knockdown system in vitro, we investigated whether the recently reported A-to-I editing sites in CYFIP2, filamin A (FLNA), bladder cancer associated protein (BLCAP), and insulin-like growth factor binding protein 7 (IGFBP7) mRNAs (35) are the substrates of ADAR1 or ADAR2 in humans. We also examined whether these mRNAs form complexes with ADAR2 in humans, by means of ADAR2-immunoprecipitation of nuclear extracts of human cerebellum (36) .
Using RNAi knockdown, we found that CYFIP2 mRNA had an ADAR2-mediated editing position and that BLCAP mRNA had an ADAR1-mediated editing position (Table 1) (36, 37) . In addition, we found that ADAR2 formed complexes with mRNAs with ADAR2-mediated editing positions including GluR2, kv1.1, and CYFIP2 mRNAs, particularly when the editing sites were edited in human cerebellum by means of the immunoprecipitation method. CYFIP2 mRNA was ubiquitously expressed in human tissues with variable extents of K/E site-editing ( Fig. 2) (36, 37) . 
(37) Fig. 2 . Extent of CYFIP2-mRNA editing and level of expression of ADAR2 mRNA in human tissues. Tissues with high expression levels of ADAR2 mRNA in the β -actin mRNA base (black columns) tend to show higher extent of RNA editing at the CYFIP2 K/E site (gray columns) than those with low ADAR2 mRNA expression level, whereas some regions with high ADAR2 mRNA expression level (e.g., leukocytes) showed very low extents of CYFIP2 mRNA editing. Value represents the mean ± S.D. for multiple samples of cerebral cortex (n = 4), cerebellum (n = 5), and leukocytes (n = 7) and represents the mean for the rest of tissue samples (n < 3). Reproduced from Ref. 37 with permission.
Conclusion
CYFIP2 mRNA is particularly abundant in the central nervous system including motor neurons in the spinal cord, and the extent of site-editing in it ranges from 30% to 85% in the human central nervous system (37, 38) . Because ADAR2 underactivity may be a cause of death of motor neurons in sporadic ALS, the CYFIP2 K/E site, a newly identified ADAR2-mediated editing position, may become a useful tool for ALS research. To investigate whether deficiency of ADAR2 activity induces slow neuronal death as seen in motor neurons of sporadic ALS patients, we have generated genetically modified mice in which the ADAR2 gene is conditionally knocked out in motor neurons using the Cre-loxP system.
